These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 35144648)

  • 1. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.
    Nobari ST; Nojadeh JN; Talebi M
    J Transl Med; 2022 Feb; 20(1):82. PubMed ID: 35144648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma.
    Fang Y; Hou J
    Mil Med Res; 2021 Jan; 8(1):9. PubMed ID: 33504363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
    Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
    Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy.
    Lee L; Lim WC; Galas-Filipowicz D; Fung K; Taylor J; Patel D; Akbar Z; Alvarez Mediavilla E; Wawrzyniecka P; Shome D; Reijmers RM; Gregg T; Wood L; Day W; Cerec V; Ferrari M; Thomas S; Cordoba S; Onuoha S; Khokhar N; Peddareddigari V; Al-Hajj M; Cavet J; Zweegman S; Rodriguez-Justo M; Youg K; Pule M; Popat R
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37399355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy.
    Quazi S
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e392-e404. PubMed ID: 34992008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
    Ferment B; Arnulf B
    Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
    Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCMA-targeted immunotherapy for multiple myeloma.
    Yu B; Jiang T; Liu D
    J Hematol Oncol; 2020 Sep; 13(1):125. PubMed ID: 32943087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
    Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.
    Rees MJ; Kumar S
    Leuk Lymphoma; 2024 Mar; 65(3):287-300. PubMed ID: 38354090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF.
    He C; Zhang M; Liu L; Han Y; Xu Z; Xiong Y; Yan F; Su D; Chen H; Zheng Y; Cheng F
    Acta Biomater; 2022 Apr; 143():406-417. PubMed ID: 35218967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting B-cell maturation antigen in multiple myeloma.
    Tai YT; Anderson KC
    Immunotherapy; 2015; 7(11):1187-99. PubMed ID: 26370838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
    Schmidts A; Ormhøj M; Choi BD; Taylor AO; Bouffard AA; Scarfò I; Larson RC; Frigault MJ; Gallagher K; Castano AP; Riley LS; Cabral ML; Boroughs AC; Velasco Cárdenas RM; Schamel W; Zhou J; Mackay S; Tai YT; Anderson KC; Maus MV
    Blood Adv; 2019 Nov; 3(21):3248-3260. PubMed ID: 31698455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.